Answers are grounded in this paper and cite their sources.
Pancreatic cancer is known to have a high mortality rate, and its early diagnosis remains challenging due to the occult location of the pancreas. Exosomes derived from pancreatic cancer cells specifically express glypican-1, which may provide a liquid biopsy opportunity for the early diagnosis of pancreatic cancer. Herein, an inductively coupled plasma mass spectrometry (ICP-MS) and photothermal dual-readout platform was proposed for the ultrasensitive and point-of-care analysis of pancreatic cancer exosomes. In our design, exosomes were specifically captured by the sandwich immunoassay, and simultaneously, alkaline phosphatase was introduced in a low-background manner. The alkaline phosphatase triggered the hydrolysis of l -ascorbic acid 2-phosphate to produce ascorbic acid, followed by the etching of Fe 3 O 4 @MnO 2 nanoflowers. As a result, the Mn 2+ generated by etching stripped off the Fe 3 O 4 and was quantified using ICP-MS. Meanwhile, the reduced Fe 3 O 4 @MnO 2 was applied for the photothermal assay by oxidizing dopamine with MnO 2 . The protocol exhibits a detection limit down to 19.1 particles mL –1, which is the most sensitive protocol reported so far. To our knowledge, this is the first endeavor for exosome quantification using ICP-MS and photothermal methods. The developed dual-readout platform not only is capable of distinguishing pancreatic cancer patients from healthy people, but also shows excellent discernibility of individual differences at low concentrations of exosomes. This dual-readout assay is a promising platform for the ultrasensitive and point-of-care detection of exosomes in liquid biopsy-based early cancer diagnosis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: